Hormonal
Other GLP-1 receptor agonists and SGLT2 inhibitors, including semaglutide, dulaglutide, and canagliflozin, did not demonstrate a statistically significant elevation in gynecologic tumor risk compared to controls.
If you are taking other GLP-1 receptor agonists (like semaglutide or dulaglutide) or SGLT2 inhibitors (like canagliflozin or empagliflozin), this network meta-analysis did not find a statistically significant increase in gynecologic tumor risk for these agents. However, the authors note that more data is needed to confirm whether the association with tirzepatide is causal.
No other regimen demonstrated a significant elevation in risk.
Why this rating
Based on the same large network meta-analysis.
Source
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials
Ping‐Tao Tseng et al. · Journal of Hematology & Oncology · 2025
DOI 10.1186/s13045-025-01750-x
More from this paper
- High-dose tirzepatide (15mg/week) is associated with a significantly increased risk of overall gynecologic tumors compared to controls, with an odds ratio of 2.37.Good
- Both high-dose (15mg/week) and low-dose (5mg/week) tirzepatide are associated with a significantly elevated risk of intra-uterus tumors.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →